Results 51 to 60 of about 263,760 (324)
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Nature Communications, 2016 miRNAs can function either as proto-oncogenes or tumour suppressors in several cancers; however their function in tumour initiating cells is unclear. Here, Zhang et al.
Wen Cai Zhang +21 more
doaj +1 more source
Characterization of a human cell line stably over-expressing the candidate oncogene, dual specificity phosphatase 12. [PDF]
PLoS ONE, 2011 Analysis of chromosomal rearrangements within primary tumors has been influential in the identification of novel oncogenes. Identification of the "driver" gene(s) within cancer-derived amplicons is, however, hampered by the fact that most amplicons ...
Erica L Cain +2 more
doaj +1 more source
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Oncogenes in immune cells as potential therapeutic targets
ImmunoTargets and Therapy, 2018 Gulnur K Zakiryanova,1 Sarah Wheeler,2 Michael R Shurin2 1Department Biophysics and Biomedicine, Faculty Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan; 2Division of Clinical Immunopathology, Department of Pathology ...
Zakiryanova GK, Wheeler S, Shurin MR
doaj
Научно-технический вестник информационных технологий, механики и оптикиThe loss of the regulatory function of tumor suppression genes and mutations in Proto-oncogene are the common underlying mechanisms for uncontrolled tumor growth in the varied complex of disorders known as cancer.
M. Vijayalakshmi, M. Vallinayagi
doaj +1 more source
The non-coding oncogene: a case of missing DNA evidence?
Frontiers in Genetics, 2012 The evidence that links classical protein-coding proto-oncogenes and tumor suppressors, such as MYC, RAS, P53, and RB, to carcinogenesis is indisputable. Multiple lines of proof show how random somatic genomic alteration of such genes (e.g.
Puja eShahrouki, Erik eLarsson
doaj +1 more source
Potential malignant transformation in the gastric mucosa of immunodeficient mice with persistent Mycoplasma penetrans infection. [PDF]
PLoS ONE, 2017 Mycoplasma infection has been reported in immunocompromised cancer patients; nevertheless, it is not clear if persistent Mycoplasma infection could facilitate the proliferation of cancer cells in immunocompromised organisms.
Shuyan Cao +5 more
doaj +1 more source
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris +10 more
wiley +1 more source